E. Lim Et Al. , "The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study," 42nd Annual San Antonio Breast Cancer Symposium , vol.80, San-Antonio, Northern Mariana Islands, 2019
Lim, E. Et Al. 2019. The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study. 42nd Annual San Antonio Breast Cancer Symposium , (San-Antonio, Northern Mariana Islands).
Lim, E., Boyle, F., Okera, M., Loi, S., SEZGİN GÖKSU, S., van Hal, G., ... Hartman, D. G.(2019). The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study . 42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands
Lim, Elgene Et Al. "The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study," 42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 2019
Lim, Elgene Et Al. "The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study." 42nd Annual San Antonio Breast Cancer Symposium , San-Antonio, Northern Mariana Islands, 2019
Lim, E. Et Al. (2019) . "The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study." 42nd Annual San Antonio Breast Cancer Symposium , San-Antonio, Northern Mariana Islands.
@conferencepaper{conferencepaper, author={Elgene Lim Et Al. }, title={The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study}, congress name={42nd Annual San Antonio Breast Cancer Symposium}, city={San-Antonio}, country={Northern Mariana Islands}, year={2019}}